Larance Ronsard

Dr. Larance Ronsard

Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Cell
Verified
Journal Article
Closed access
ISIan Setliff
Ian Setliff
ASAndrea R. Shiakolas
Andrea R. Shiakolas
KPKelsey A. Pilewski
Kelsey A. Pilewski
AMAmyn A. Murji
Amyn A. Murji
RMRutendo E. Mapengo
Rutendo E. Mapengo
IGIvelin Georgiev
Ivelin Georgiev

8 April 2022 in Nature Methods
Verified
Journal Article
Closed access
PDF file
CDConnor S. Dobson
Connor S. Dobson
ARAnna N. Reich
Anna N. Reich
SGStephanie Gaglione
Stephanie Gaglione
BSBlake E. Smith
Blake E. Smith
EKEllen J. Kim
Ellen J. Kim
MBMichael E. Birnbaum
Michael E. Birnbaum

1 October 2019 in Immunity
Verified
Journal Article
Closed access
MSMaya Sangesland
Maya Sangesland
LRLarance Ronsard
Larance Ronsard
SKSamuel W. Kazer
Samuel W. Kazer
JBJulia Bals
Julia Bals
SBSeyhan Boyoglu-Barnum
Seyhan Boyoglu-Barnum
DLDaniel Lingwood
Daniel Lingwood

30 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
EWEike-Christian Wamhoff
Eike-Christian Wamhoff
LRLarance Ronsard
Larance Ronsard
JFJared Feldman
Jared Feldman
GKGrant A. Knappe
Grant A. Knappe
BHBlake M. Hauser
Blake M. Hauser
MBMark Bathe
Mark Bathe
Protein-based virus-like particles (P-VLPs) are commonly used to spatially organize antigens and enhance humoral immunity through multivalent antigen display. However, P-VLPs are thymus-dependent antigens that are themselves immunogenic and can induce B cell responses that may neutralize the platform. Here, we investigate thymus-independent DNA origami as an alternative material for multivalent antigen display using the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, the primary target of neutralizing antibody responses. Sequential immunization of mice with DNA-based VLPs (DNA-VLPs) elicits protective neutralizing antibodies to SARS-CoV-2 in a manner that depends on the valency of the antigen displayed and on T cell help. Importantly, the immune sera do not contain boosted, class-switched antibodies against the DNA scaffold, in contrast to P-VLPs that elicit strong B cell memory against both the target antigen and the scaffold. Thus, DNA-VLPs enhance target antigen immunogenicity without generating scaffold-directed immunity and thereby offer an important alternative material for particulate vaccine design.

10 January 2018 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
BKBinod Kumar
Binod Kumar
KAKumari Asha
Kumari Asha
MKMadhu Khanna
Madhu Khanna
LRLarance Ronsard
Larance Ronsard
CMClement Adebajo Meseko
Clement Adebajo Meseko
MSMelvin Sanicas
Melvin Sanicas

10 December 2021 in Science Immunology
Verified
Journal Article
Open access
JFJared Feldman
Jared Feldman
JBJulia Bals
Julia Bals
CAClara G. Altomare
Clara G. Altomare
KDKerri St. Denis
Kerri St. Denis
ELEvan C. Lam
Evan C. Lam
ASAaron G. Schmidt
Aaron G. Schmidt
Naive antibodies targeting the SARS-CoV-2 receptor binding domain can be isolated from SARS-CoV-2 seronegative individuals.